CEL-SCI logo

CEL-SCI Stock

StockStock
ISIN: US1508376076
Ticker: CVM
US1508376076
CVM

Price

Historical dividends and forecast

All dividend data

 


$62.50

CHART BY

Frequently asked questions

What is CEL-SCI's market capitalization?

The market capitalization of CEL-SCI is $44.28M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for CEL-SCI?

CEL-SCI's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.581. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for CEL-SCI's stock?

Currently, 1 analysts cover CEL-SCI's stock, with a consensus target price of $7.733. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for CEL-SCI?

CEL-SCI's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$23.72M. EBITDA measures the company's overall financial performance.

What is the free cash flow of CEL-SCI?

CEL-SCI has a free cash flow of -$19.11M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of CEL-SCI's stock?

The 5-year beta for CEL-SCI is 0.62. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does CEL-SCI have, and what sector and industry does it belong to?

CEL-SCI employs approximately 43 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of CEL-SCI's shares?

The free float of CEL-SCI is 59.70M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$44.28M

5Y beta

 
0.62

EPS (TTM)

 
-$0.581

Free Float

 
59.70M

EBITDA (TTM)

 
-$23.72M

Free Cashflow (TTM)

 
-$19.11M

Pricing

1D span
$0.688$0.748
52W span
$0.683$3.23

Analyst Ratings

The price target is $7.733 and the stock is covered by 1 analysts.

Buy

1

Hold

0

Sell

0

Information

CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.

43

Biotechnology & Drugs

Health Care

Identifier

ISIN

US1508376076

Primary Ticker

CVM

Knockouts

Join the conversation